{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-052542","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.167300+00:00","generated_at":"2026-05-14T22:54:31.314188+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026","bullets":["API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.","All manufacturing payments completed; no additional cash outlays anticipated.","Supports potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.","Ongoing Phase 2 trial in advanced ovarian cancer continues enrolling under amended protocol.","Phase 2 trial of stenoparib + temozolomide for relapsed SCLC recruiting across multiple VA sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-052542","json":"https://secwatch.observer/filing/0001213900-26-052542.json","markdown":"https://secwatch.observer/filing/0001213900-26-052542.md","text":"https://secwatch.observer/filing/0001213900-26-052542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026052542/0001213900-26-052542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026052542/ea0289243-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:54:31.314188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}